Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U, Delrio P.

Therap Adv Gastroenterol. 2016 Nov;9(6):861-886. Review.

3.

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.

Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M.

Onco Targets Ther. 2016 Jul 28;9:4695-703. doi: 10.2147/OTT.S102891.

4.

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.

Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC.

World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222.

5.

Pharmacologic resistance in colorectal cancer: a review.

Hammond WA, Swaika A, Mody K.

Ther Adv Med Oncol. 2016 Jan;8(1):57-84. doi: 10.1177/1758834015614530. Review.

6.

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.

Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T.

Sci Rep. 2015 Dec 22;5:18678. doi: 10.1038/srep18678.

8.

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.

Kim ST, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC.

BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y.

9.

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F.

Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171.

10.

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A, Russo A.

Oncotarget. 2015 Sep 22;6(28):24780-96. doi: 10.18632/oncotarget.4959. Review.

14.

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Review.

15.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Sep 15;6(27):23281-96.

18.

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab.

Chiadini E, Scarpi E, Passardi A, Calistri D, Valgiusti M, Saragoni L, Zoli W, Amadori D, Ulivi P.

Oncol Lett. 2015 Mar;9(3):1432-1438.

19.

Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapy.

Luo W, He WT, Wen Q, Chen S, Wu J, Chen XP, Ma L.

Am J Cancer Res. 2014 Nov 19;4(6):924-33.

20.

Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.

Wang W, Zhang Y, Lv M, Feng J, Peng H, Geng J, Lin Z, Zhou T, Li X, Shen B, Ma Y, Qiao C.

J Ovarian Res. 2014 Nov 26;7:103. doi: 10.1186/s13048-014-0103-5.

Items per page

Supplemental Content

Support Center